Ma Hong-Bo, Huang Tao, Han Feng, Chen Wei-Yu
Department of Hepatobiliary and Pancreatic Surgery, Henan Tumor Hospital, the Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China.
Asian Pac J Cancer Prev. 2012;13(6):2841-6. doi: 10.7314/apjcp.2012.13.6.2841.
Many studies have investigated the association between the MDM2 promoter SNP309 T/G polymorphism and liver cancer risk, but inconsistencies make drawwing definitive conclusions difficult.
We therefore searched main databases for articles relating MDM2 SNP309 T/G polymorphism to risk of liver cancer in humans and estimated summary odds ratio (OR) with 95% confidence intervals (95% CI) to assess the possible association in a meta-analysis.
The main analysis revealed no significant heterogeneity, and the pooled ORs of fixed-effects were all significant (for G versus T, OR = 1.59, 95% CI 1.42-1.78; for GG versus TT, OR = 2.45, 95% CI 1.93-3.12; for GT versus TT, OR = 1.70, 95% CI 1.38-2.09; for GG versus GT, OR = 1.49, 95% CI 1.24-1.79; for GG and GT versus TT, OR = 1.95, 95% CI 1.61-2.38; for GG versus TT and GT, OR = 1.73, 95% CI 1.46-2.07). Subgroup analyses by ethnicity and sensitivity analyses both showed associations to remain significant.
The present meta-analysis of available data showed a significant association between the MDM2 SNP309 T/G polymorphism and liver cancer risk, the MDM2 SNP309 G allele contributing to increased risk in both Asians and Caucasians in a graded, dose-dependent fashion.
许多研究调查了MDM2启动子SNP309 T/G多态性与肝癌风险之间的关联，但结果不一致，难以得出明确结论。
因此，我们在主要数据库中搜索了有关MDM2 SNP309 T/G多态性与人类肝癌风险的文章，并估计了汇总比值比（OR）及95%置信区间（95%CI），以在荟萃分析中评估可能的关联。
主要分析显示无显著异质性，固定效应的合并OR均具有显著性（G对T，OR = 1.59，95%CI 1.42 - 1.78；GG对TT，OR = 2.45，95%CI 1.93 - 3.12；GT对TT，OR = 1.70，95%CI 1.38 - 2.09；GG对GT，OR = 1.49，95%CI 1.24 - 1.79；GG和GT对TT，OR = 1.95，95%CI 1.61 - 2.38；GG对TT和GT，OR = 1.73，95%CI 1.46 - 2.07）。按种族进行的亚组分析和敏感性分析均显示关联仍然显著。
目前对现有数据的荟萃分析表明，MDM2 SNP309 T/G多态性与肝癌风险之间存在显著关联，MDM2 SNP309 G等位基因以分级、剂量依赖的方式导致亚洲人和白种人患癌风险增加。
